江泽飞:浅谈乳腺癌临床治疗前景medsci专访CSCO2014:

2014-09-19 MedSci MedSci原创

“第十七届全国临床肿瘤学术大会暨2014年CSCO学术年会”会议于2014年9月17-21日在厦门国际会议中心盛大开幕。在19日上午的乳腺癌内分泌治疗论坛上,来自军事医学科学院附属307医院乳腺肿瘤科主任江泽飞教授在会议上带来了“2014 中国乳腺癌内分泌治疗专家共识讨论”的精彩讲座。 乳腺癌这50年的发展很迅速,从早期肿瘤的发现,早期诊断,基因检测,到现在的乳腺癌手术局部治疗和全身治疗的进步显

“第十七届全国临床肿瘤学术大会暨2014年CSCO学术年会”会议于2014年9月17-21日在厦门国际会议中心盛大开幕。在19日上午的乳腺癌内分泌治疗论坛上,来自军事医学科学院附属307医院乳腺肿瘤科主任江泽飞教授在会议上带来了“2014 中国乳腺癌内分泌治疗专家共识讨论”的精彩讲座。

乳腺癌这50年的发展很迅速,从早期肿瘤的发现,早期诊断,基因检测,到现在的乳腺癌手术局部治疗和全身治疗的进步显而易见。MedSci就乳腺癌治疗的相关问题对江泽飞教授进行了简单的采访。

MedSci通讯员:江泽飞教授,您好,感谢您接受MedSci的采访。近些年来,国际上乳腺癌研究获得得较大的进展,包括指南共识的发布,让乳腺癌管理更加标准规范化,也属于今年CSCO的一个主题。请问您觉得这些发展对我国临床治疗和研究会有哪些影响?

江泽飞教授:总体来说是学习、吸收、创新、提高。这些年来,我们在和国际的交往和走出去的过程中的确学习到了国际上先进的理念,和新的技术、诊断方法。更多的国际指南引入到了中国,并且,我们自己也参与了一些国际指南。以前我们只是听说,后来我们是拿来用,现在我们可以将自己的实践经验和体会反馈到国际,因为我们现在已经进入国际共识和指南专家团。所以应该说,我们的确学习和吸收到了很多的精华,提高了咱们的诊疗水平。

MedSci通讯员:“维持治疗与全程管理”的乳腺癌治疗新理念自提出后,得到了业内专家的一致肯定。乳腺癌治疗的“私人订制”越来越受到追捧,您可否谈谈乳腺癌的个体化治疗,在国内实施的前景和困难?

江泽飞教授:乳腺癌治疗的“私人定制”毋庸置疑是好的。现在都讲究个体化治疗,好比做衣服,量身定制的肯定是最合身的,但是不是每个人都能做到什么样的衣服都去私人定制。全程管理策略的制定就是需要根据乳腺癌的不同阶段、不同类型进行调整,为患者提供“量身订制”的多学科综合治疗方案。它建立在乳腺癌规范化诊疗的基础上,强调多学科共同写作,并且贯穿从疾病诊断到康复的全过程,从疾病治疗、体型重塑、心理康复等多个方面帮助乳腺癌患者更好地抗击疾病,获得新生。个体的差异很大,我们都在说“个体化”,但是有时候我们也不希望“个体化”,过于个体化也会失去规范。同样的,过于规范的有板有眼,也会失去个性化。其实一个病人需要治疗和适合治疗,以及和是否完成顺利治疗,这之间是有区别的,所以我觉得,这就是所谓的“私人定制”。我们希望从开始的诊断到治疗过程中就能体现到根据患者个体的情况实施动态监控,并且及时调整方案,这种“私人定制”这是很理想的状态。现在这个也在慢慢实现,我们推动“全程管理”就是为了可以在一定程度达到这种理想状态,目前我们国家在技术和设备上都没有问题,只是在理念上需要做一些转变,不过我认为前景还是比较乐观的,在共同指南和规范下,大家的理念终会改变过来。我们也希望这个方案制定好后,不要总是改变,无论在哪里,基本方案应该一致才行。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1755837, encodeId=9a711e5583794, content=<a href='/topic/show?id=57a564331cd' target=_blank style='color:#2F92EE;'>#江泽飞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64331, encryptionId=57a564331cd, topicName=江泽飞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3c337051995, createdName=jktdtl, createdTime=Wed Jan 07 09:52:00 CST 2015, time=2015-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703167, encodeId=640b1e03167f1, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat May 23 12:52:00 CST 2015, time=2015-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797745, encodeId=67d81e9774553, content=<a href='/topic/show?id=cccd23e31c0' target=_blank style='color:#2F92EE;'>#乳腺癌临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23731, encryptionId=cccd23e31c0, topicName=乳腺癌临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Mar 26 23:52:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525789, encodeId=b82f1525e89ab, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Sun Sep 21 06:52:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606284, encodeId=ba8a1606284d9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 21 06:52:00 CST 2014, time=2014-09-21, status=1, ipAttribution=)]
    2015-01-07 jktdtl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1755837, encodeId=9a711e5583794, content=<a href='/topic/show?id=57a564331cd' target=_blank style='color:#2F92EE;'>#江泽飞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64331, encryptionId=57a564331cd, topicName=江泽飞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3c337051995, createdName=jktdtl, createdTime=Wed Jan 07 09:52:00 CST 2015, time=2015-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703167, encodeId=640b1e03167f1, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat May 23 12:52:00 CST 2015, time=2015-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797745, encodeId=67d81e9774553, content=<a href='/topic/show?id=cccd23e31c0' target=_blank style='color:#2F92EE;'>#乳腺癌临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23731, encryptionId=cccd23e31c0, topicName=乳腺癌临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Mar 26 23:52:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525789, encodeId=b82f1525e89ab, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Sun Sep 21 06:52:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606284, encodeId=ba8a1606284d9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 21 06:52:00 CST 2014, time=2014-09-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1755837, encodeId=9a711e5583794, content=<a href='/topic/show?id=57a564331cd' target=_blank style='color:#2F92EE;'>#江泽飞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64331, encryptionId=57a564331cd, topicName=江泽飞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3c337051995, createdName=jktdtl, createdTime=Wed Jan 07 09:52:00 CST 2015, time=2015-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703167, encodeId=640b1e03167f1, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat May 23 12:52:00 CST 2015, time=2015-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797745, encodeId=67d81e9774553, content=<a href='/topic/show?id=cccd23e31c0' target=_blank style='color:#2F92EE;'>#乳腺癌临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23731, encryptionId=cccd23e31c0, topicName=乳腺癌临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Mar 26 23:52:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525789, encodeId=b82f1525e89ab, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Sun Sep 21 06:52:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606284, encodeId=ba8a1606284d9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 21 06:52:00 CST 2014, time=2014-09-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1755837, encodeId=9a711e5583794, content=<a href='/topic/show?id=57a564331cd' target=_blank style='color:#2F92EE;'>#江泽飞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64331, encryptionId=57a564331cd, topicName=江泽飞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3c337051995, createdName=jktdtl, createdTime=Wed Jan 07 09:52:00 CST 2015, time=2015-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703167, encodeId=640b1e03167f1, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat May 23 12:52:00 CST 2015, time=2015-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797745, encodeId=67d81e9774553, content=<a href='/topic/show?id=cccd23e31c0' target=_blank style='color:#2F92EE;'>#乳腺癌临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23731, encryptionId=cccd23e31c0, topicName=乳腺癌临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Mar 26 23:52:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525789, encodeId=b82f1525e89ab, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Sun Sep 21 06:52:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606284, encodeId=ba8a1606284d9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 21 06:52:00 CST 2014, time=2014-09-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1755837, encodeId=9a711e5583794, content=<a href='/topic/show?id=57a564331cd' target=_blank style='color:#2F92EE;'>#江泽飞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64331, encryptionId=57a564331cd, topicName=江泽飞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3c337051995, createdName=jktdtl, createdTime=Wed Jan 07 09:52:00 CST 2015, time=2015-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703167, encodeId=640b1e03167f1, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Sat May 23 12:52:00 CST 2015, time=2015-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797745, encodeId=67d81e9774553, content=<a href='/topic/show?id=cccd23e31c0' target=_blank style='color:#2F92EE;'>#乳腺癌临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23731, encryptionId=cccd23e31c0, topicName=乳腺癌临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Thu Mar 26 23:52:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525789, encodeId=b82f1525e89ab, content=<a href='/topic/show?id=c93e228e889' target=_blank style='color:#2F92EE;'>#临床治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22878, encryptionId=c93e228e889, topicName=临床治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a68911667380, createdName=xuyong527, createdTime=Sun Sep 21 06:52:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606284, encodeId=ba8a1606284d9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 21 06:52:00 CST 2014, time=2014-09-21, status=1, ipAttribution=)]

相关资讯

CSCO 2014:SBRT在肿瘤放疗中的应用

肿瘤放射治疗论坛地点:2楼2号会议室时间:9月20日17:10~17:30         报告者:解放军空军总医院夏廷毅教授 体部立体定向放疗(SBRT)是重要的现代放疗技术,体现了肿瘤放疗的最高水平。与传统放疗相比,四维CT定位、影像引导、呼吸补偿、靶区追踪、共面或非共面旋转聚焦等技术共同实现了SBRT对肿

CSCO 2014:食管癌的放疗进展

肿瘤放射治疗论坛地点:2楼2号会议室时间:9月20日15:45~16:10         报告者:上海交通大学附属胸科医院  傅小龙 食管鳞癌初次治疗的总体策略制定主要依赖于患者一般情况、原发病灶所在部位以及治疗前的临床分期。其中最主要参考指标为临床分期。近年来,一些新的手术方式用于早期食管癌的治疗

CSCO 2014:肿瘤放射治疗论坛:把放疗学科更好地展现出来

中国医学科学院肿瘤医院、肿瘤放射治疗论坛策划负责人、非小细胞肺癌论坛-放化疗专场共同负责人王绿化 根据不同癌种或不同领域来安排总负责人来统筹安排,这是今年CSCO年会的一个重要举措,也是一个新变化。对于我主要负责的“肿瘤放射治疗论坛”和作为负责人之一的“非小细胞肺癌论坛-放化疗专场”而言,今年也有了一些新的内容和形式。 非小细胞肺癌论坛-放化疗专场NSCLC放化疗领域当前热门话题 本专场

CSCO 2014:c-MET肿瘤通路论坛——价值已被认识,治疗仍待研究

9月18日上午,体现今年CSCO年会跨学科专题设置特色的c-MET肿瘤通路论坛伴随年会的“第一波学术热潮”一早开场。现场不但邀请领域内重要学者报告,演讲内容涉及从基础到临床的研究进展,非常值得关注,而且,听众的热情也令人瞩目。专场共同主席于丁教授的一句戏言,生动描述了会场的拥挤状况——“虽然我们今天研究‘通路’,但显然没能做到会场的‘通路’顺畅。” MET在肿瘤生成中扮演重要角色,MET异常导致

CSCO 2014:局部晚期非小细胞肺癌外科治疗的共识与争议

 非小细胞肺癌论坛(1楼1F-1会议室)时间:9月19日11:20~11:50 报告者:江苏省肿瘤医院许林 肺癌扩大切除是指在常规肺癌外科治疗原则基础上切除原发肿瘤及其相邻器官,如心脏大血管、气管降嵴、胸壁、膈肌、心包、脊柱、食管等的受侵部分,同时加以修复、重建或置换。目前,扩大性切除的范围有进一步发展,许多肿瘤侵及心脏大血管、气管隆嵴的局部晚期肺癌得到完全性切除。 报告认为,局部

CSCO 2014:肝癌专场--念念不忘,必有反响

        解放军南京八一医院秦叔逵教授 CSCO年会的肝癌专题论坛已经开展了4年了,本次论坛内容也是由CSCO肝癌专家委员会成员共同讨论设置的。简而言之,在肝癌的系统治疗方面的进展,主要有三大方面: 分子靶向治疗 以索拉非尼为代表的药物,开启了分子靶向药物治疗肝癌的“阿里巴巴大门”,可惜后来的许多新药研